WO2004083856A1 - 大腸癌マーカー検出方法 - Google Patents
大腸癌マーカー検出方法 Download PDFInfo
- Publication number
- WO2004083856A1 WO2004083856A1 PCT/JP2003/011972 JP0311972W WO2004083856A1 WO 2004083856 A1 WO2004083856 A1 WO 2004083856A1 JP 0311972 W JP0311972 W JP 0311972W WO 2004083856 A1 WO2004083856 A1 WO 2004083856A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rna
- biological sample
- detecting
- cdna
- sample
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
Definitions
- the present invention provides a method for diagnosing colorectal cancer, which comprises extracting RNA from a biological sample, which method does not include a means for separating cellular components from the biological sample. It relates to the detection method.
- Colorectal cancer deaths are on the rise. Colorectal cancer is the fourth most common type of cancer death among males and the second most common type of female cancer death (1999 cancer death statistics). In addition, in the 2015 estimate of cancer patients, it is estimated that males and females will be ranked first, and comprehensive colorectal cancer measures, including secondary prevention, are required. It is one of the most effective methods.
- the fecal occult blood test has low sensitivity and specificity (having a sensitivity of 30 to 90% and a specificity of 70 to 98%) because the appearance of hemoglobin in feces is not specific to tumors, and is therefore a false negative. And that there are considerable false positives.
- diagnosis of colorectal cancer may be performed after screening by immunological fecal occult blood test, or at the same time, a combination of whole colonoscopy or enema and sigmoid colonoscopy.
- the disadvantage is that it takes a lot of time and effort.
- the method using these DNAs is non-invasive and can directly detect changes in cancer cells, has the feature of high specificity, and is considered to be a promising method. It has the disadvantages of being less sensitive than certain fecal occult blood tests, and requiring considerable time and effort.
- mRNA such as protein kinase C (PKC) in feces
- PLC protein kinase C
- a method of detecting mRNA such as protein kinase C (PKC) in feces has been developed to detect gene expression more directly (Davidson et al.) (LADavidson, et al.), Carcinogenesis (Vol. 19, No. 2, 1998, pp. 253-257); Alexander and Reichatt (RJAlexander and RFRaicht) ), Digestive Diseases and Sciences, Vol. 43, No. 12, 1998, pp. 2652-26558; by Yamao et al. (T. Yamao et. al.), Gastroenterology
- RNA could not be easily and efficiently extracted from a small amount of feces, and a sensitivity exceeding that of the fecal occult blood method could not be obtained.
- RNA is unstable compared to DNA, and is present universally in all biological samples and always poses the risk of degradation by the extremely stable RNase. Because of the exposure, strict control is required in the RT-PCR method as well as in the RNA purification process and after the purification so that RNase is not contaminated.
- RNA was extracted from a biologically crude sample of feces, a step of separating the cell fraction in advance was required to eliminate the influence of RNase.
- RNA directly from stool which contains an enormous amount of RNase derived from an extremely large number of microorganisms.At least, cell fractions must be removed to remove exogenous RNase derived from microorganisms, etc. Separation of the minutes was considered essential.
- an object of the present invention is to provide a non-invasive and simple method for detecting a tumor marker for colorectal cancer diagnosis, which has sensitivity and specificity exceeding those of the conventional fecal occult blood test.
- the present invention comprises the following steps:
- a method for preparing a sample for extracting RNA used in a method for detecting a tumor marker for colorectal cancer diagnosis comprising:
- the method does not include a step of separating cell components from a biological sample.
- the collected biological sample is preferably frozen.
- the present invention provides the method, wherein the RNase inhibitor is guanidine thiocyanate. The above method.
- the present invention is the above method, wherein the biological sample is feces. Further, the present invention provides, in addition to the steps of the above method, the following steps:
- the present invention is a method for detecting a tumor marker for colorectal cancer diagnosis, wherein the tumor marker is COX-2.
- the present invention provides the following means:
- a kit for preparing a sample for extracting RNA used in a method for detecting a tumor marker for colorectal cancer diagnosis comprising:
- the kit is characterized by not including a means for separating cell components from a biological sample.
- kit of the present invention preferably includes a means for freezing the collected biological sample.
- the present invention is the above-mentioned kit, wherein the RNase inhibitor is guanidine thiocyanate.
- the present invention is the above-mentioned kit, wherein the biological sample is feces.
- the present invention further provides the following means:
- RNA means for extracting RNA from a sample for extracting the obtained RNA
- a kit for detecting a tumor marker for colorectal cancer diagnosis comprising:
- the present invention is the above kit, wherein the tumor marker is COX-2.
- FIG. 1 shows the electrophoresis results of Example 2.
- Lane 1 is the total RNA extracted from human feces by the method of Alexander et al.
- Lane 2 is total RNA extracted from human feces by the method of the present invention.
- Lane 3 is total RNA extracted from human colon cancer tissue.
- Lane M is the molecular weight marker.
- ribonuclease inhibitor of the present invention examples include guanidine thiocyanate, isogen (Isogene), UltraSpec II (registered trademark) (U1traspec II) and the like.
- Examples of the biological sample of the present invention include animal and plant tissues, bodily fluids, excreta, and the like, and are preferably feces, and more preferably human feces.
- the biological sample of the present invention can be used as it is or, optionally, frozen.
- the freezing method can use any conventional technique, and is preferably a method using liquid nitrogen.
- the freezing temperature is a storage temperature of -1 to 196 ° C, preferably, 120 to 196 ° C (: preferably, _75 to 196, more preferably, -110 to 196 °. C, most preferably-196 ° C.
- the frozen sample may be stored frozen.
- the storage temperature is from 170 to 196 ° C, preferably from 110 to -196 ° C, more preferably -196 ° C.
- the storage period is 1 day to 10 years, preferably 1 day to 3 years, more preferably 1 day to 1 year.
- the tumor markers used in the present invention include COX-2, matrix meta-oral protease (MMP;), c-met, CD44 mutant (variants), EGF_R, EF-1, Wnt-2, and Bradion. (Bradeion), SKP 2, KP C-1, K
- PC-2 PC-2, PRL-3, Angiogenin, Integrin, Snail1, Dysadherin, etc., and preferably COX-2.
- the above steps c) to e) are called the RT-PCR method.
- Sekiya The method can be performed according to the description of Tsugio et al., Frontline of PCR Method, 1997, Kyoritsu Shuppan, pp. 187-196.
- RNA Extraction Kit RNA Extraction Kit
- reverse transcription refers to the conversion of RNA into complementary DNA (cDNA) using reverse transcriptase.
- the reverse transcription reaction is usually buffer one, Mg C 1 2 or salts KC 1 and the like, Jichiosurei! (DTT), primers, deoxyribonucleotides, RNase inhibitor and reverse transcriptase.
- DTT Jichiosurei!
- primers deoxyribonucleotides
- RNase inhibitor reverse transcriptase.
- proteins such as gelatin and albumin, surfactants and the like can also be added.
- PCR is usually used for amplification of cDNA following reverse transcription.
- Reaction of PC R typically includes buffer mono-, salts such as MgC 1 2 and KC 1, primers, de O alkoxy lipoic nucleotides, and a thermostable polymerase.
- the above salts can be suitably used after being changed to other salts.
- proteins such as gelatin and albumin, dimethyl sulfoxide ⁇ ⁇ surfactant and the like can be added.
- the LAMP method Japanese Patent No. 3313358
- ICAN method JP-A-2001-136965
- the term “primer” refers to an oligonucleotide that functions as a synthesis starting point in cDNA synthesis or nucleic acid amplification.
- the primer is preferably single-stranded, but Japanese-stranded may also be used.
- the primer is double-stranded, it is desirable that the primer be single-stranded before the amplification reaction.
- Primers can be synthesized according to known methods, and can also be isolated from living organisms.
- the reverse transcriptase used in the reverse transcription reaction means an enzyme that can reverse transcribe RNA into cDNA.
- Reverse transcriptases include those derived from retroviruses such as RAV (Rous associated virus) and AMV (Avian myeloblastosis virus), and those derived from mouse retrovirus such as MMLV (Moloney murine leukemia virus).
- RAV Raster associated virus
- AMV Avian myeloblastosis virus
- MMLV Microloney murine leukemia virus
- thermostable polymerase used for PCR include, but are not limited to, Taq polymerase.
- electrophoresis using an agarose gel can be used, but is not limited thereto.
- the kit of the present invention can also include an instruction describing the method of the present invention.
- Example 1
- the stool was dispensed as soon as possible about 1 g into a 5 ml tube as soon as possible after collection, frozen using liquid nitrogen, and stored at -80 ° C.
- human hemoglobin (Hb) in feces was measured by immunological fecal occult blood test for each sample.
- Tissues were stored at 180 ° C after freezing biopsies of cancerous and normal parts with liquid nitrogen at the time of endoscopy before treatment. After that, it was homogenized using a homogenizer, guanidine salt and phenol, and the total RNA was extracted with chloroform and ethanol.
- RNAs was reverse-transcribed using RibaScript® (registered trademark) (reaction volume 201, Wako Pure Chemical Industries, Ltd.) to obtain c DN ⁇ , and a part thereof was Gene T aq (Wako Pure Chemical Industries, Ltd.) Amplified by nested PCR
- the resulting PCR was electrophoresed on a 4% agarose gel and stained with ethidium bromide.
- the primers used were random primers for reverse transcription, and those for CE A reported by Gerhard (JJ CO, 1994) for PCR, and COX-2 was designed independently. One used. PCR was performed in the first round with 20 cycles and in the second round with 25 cycles. The primers used are shown below.
- CEA was detected in all 30 of the colorectal cancers and in 21 of the 22 control groups. In addition, it was found that both can extract RNA that can be amplified by RT-PCR.
- Non-Patent Document 6 The distribution of the amount and molecular weight of total RNA obtained from human feces was compared between the method of the present invention and the Alexander method (Non-Patent Document 6).
- total RNA was extracted from a human colon cancer tissue using a commercially available RNA extractant (Isogen, Wako Pure Chemical). The same amount of total RNA extracted from each sample was electrophoresed on agarose gel.
- RNA from human colon cancer tissue represent 28 S and 18 S rRNA.
- the smear-like portion indicates that various high molecular weight RNAs are contained in all the obtained RNAs.
- the two major bands observed in lane 2 represent 23 S and 16 S rRNA derived from intestinal bacteria. Further, since a smear-like portion is observed as in Lane 3, it is considered that various high molecular weight RNAs are contained in all RNAs obtained from feces by the method of the present invention. In contrast, in Lane 1, no band or smear was observed at all, indicating that the sample extract did not contain high molecular weight RNA.
- the desired product was obtained by RT-PCR from the sample in lane 2, but the PCR product was not obtained from the sample in lane 1.
- RNA extracted from human feces by the method of the present invention can be amplified by RT_PCR.
- the detection of COX-2 from feces by RT-PCR has a sensitivity of 90% and a specificity of 100%, so it may be superior to the conventional immunological fecal occult blood method. Proven.
- the method of the present invention requires less feces for detection and has a higher detection sensitivity than the reported detection of APC, K-ras, and p53 gene mutations, and thus requires detection. Time and labor can be saved significantly.
- the method of the present invention uses a specific and indirect method called COX-2 expression, which is a carcinogenic marker. By targeting direct events, the data obtained by the method of the present invention can provide a higher quality diagnosis.
- the method of the present invention is extremely clinically useful as a highly specific and sensitive non-invasive screening method for colorectal cancer.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/549,389 US7816077B2 (en) | 2003-03-19 | 2003-09-19 | Method of detecting colon cancer marker |
AT03816367T ATE451617T1 (de) | 2003-03-19 | 2003-09-19 | Verfahren zur erkennung eines kolonkrebsmarkers |
CA2518933A CA2518933C (en) | 2003-03-19 | 2003-09-19 | Method of detecting colon cancer marker |
EP03816367A EP1605261B1 (en) | 2003-03-19 | 2003-09-19 | Method of detecting colon cancer marker |
JP2004569601A JP4134047B2 (ja) | 2003-03-19 | 2003-09-19 | 大腸癌マーカー検出方法 |
DE60330505T DE60330505D1 (de) | 2003-03-19 | 2003-09-19 | Verfahren zur erkennung eines kolonkrebsmarkers |
AU2003264512A AU2003264512A1 (en) | 2003-03-19 | 2003-09-19 | Method of detecting colon cancer marker |
US12/460,143 US8080378B2 (en) | 2003-03-19 | 2009-07-14 | Method of detecting colon cancer marker |
US12/875,207 US8445202B2 (en) | 2003-03-19 | 2010-09-03 | Method of detecting colon cancer marker |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-75552 | 2003-03-19 | ||
JP2003075552 | 2003-03-19 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10549389 A-371-Of-International | 2003-09-19 | ||
US12/460,143 Division US8080378B2 (en) | 2003-03-19 | 2009-07-14 | Method of detecting colon cancer marker |
US12/875,207 Division US8445202B2 (en) | 2003-03-19 | 2010-09-03 | Method of detecting colon cancer marker |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004083856A1 true WO2004083856A1 (ja) | 2004-09-30 |
Family
ID=33027864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/011972 WO2004083856A1 (ja) | 2003-03-19 | 2003-09-19 | 大腸癌マーカー検出方法 |
Country Status (10)
Country | Link |
---|---|
US (3) | US7816077B2 (ja) |
EP (1) | EP1605261B1 (ja) |
JP (2) | JP4134047B2 (ja) |
CN (1) | CN100567985C (ja) |
AT (1) | ATE451617T1 (ja) |
AU (1) | AU2003264512A1 (ja) |
CA (1) | CA2518933C (ja) |
DE (1) | DE60330505D1 (ja) |
ES (1) | ES2335344T3 (ja) |
WO (1) | WO2004083856A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007018257A1 (ja) | 2005-08-10 | 2007-02-15 | Hamamatsu Foundation For Science And Technology Promotion | 大腸癌マーカー検出方法 |
WO2008093530A1 (ja) * | 2007-01-30 | 2008-08-07 | National University Corporation, Hamamatsu University School Of Medicine | 大腸癌病期検出方法 |
JP2009065900A (ja) * | 2007-09-13 | 2009-04-02 | Olympus Corp | 標的rnaの解析方法及び保存方法 |
WO2009139317A1 (ja) * | 2008-05-12 | 2009-11-19 | オリンパス株式会社 | 糞便処理方法及び糞便処理容器 |
JP2010161984A (ja) * | 2009-01-16 | 2010-07-29 | Chie Miyamoto | 癌関連遺伝子マーカーの検出方法 |
WO2012014694A1 (ja) * | 2010-07-26 | 2012-02-02 | オリンパス株式会社 | 糞便由来核酸の合成方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003264512A1 (en) * | 2003-03-19 | 2004-10-11 | Hamamatsu Foundation For Science And Technology Promotion | Method of detecting colon cancer marker |
JP4477575B2 (ja) * | 2005-12-14 | 2010-06-09 | 株式会社日立製作所 | 大腸がんの検査に使用する遺伝子セット |
JPWO2009057695A1 (ja) * | 2007-10-30 | 2011-03-10 | オリンパス株式会社 | 遺伝子解析による腺腫又はがんの検出方法 |
JP2011250757A (ja) * | 2010-06-03 | 2011-12-15 | Olympus Corp | 生体試料中の核酸検出方法 |
GB201107466D0 (en) | 2011-05-05 | 2011-06-15 | Loktionov Alexandre | Device and method for non-invasive collection of colorectal mucocellular layer and disease detection |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4843155A (en) * | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
NL8900725A (nl) | 1989-03-23 | 1990-10-16 | Az Univ Amsterdam | Werkwijze en combinatie van middelen voor het isoleren van nucleinezuur. |
US5654179A (en) * | 1990-11-14 | 1997-08-05 | Hri Research, Inc. | Nucleic acid preparation methods |
US5777099A (en) * | 1995-02-24 | 1998-07-07 | Biotecx Laboratories, Inc. | RNA separation |
WO1997035589A1 (en) * | 1996-03-26 | 1997-10-02 | Kopreski Michael S | Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer |
EP0972083A1 (en) * | 1997-04-04 | 2000-01-19 | THE TEXAS A&M UNIVERSITY SYSTEM | Noninvasive detection of colonic biomarkers using fecal messenger rna |
US6406857B1 (en) * | 1997-06-16 | 2002-06-18 | Exact Sciences Corporation | Methods for stool sample preparation |
EP0939118A1 (en) * | 1998-02-20 | 1999-09-01 | Universiteit Maastricht | Method for isolating DNA and RNA from faeces |
US6335193B1 (en) | 1999-04-15 | 2002-01-01 | Padmanabhan P Nair | Isolated colonocytes |
JP2002142767A (ja) | 2000-11-06 | 2002-05-21 | Fujirebio Inc | 癌の検出方法及び癌化の進行の有無の判定方法 |
US7101663B2 (en) * | 2001-03-02 | 2006-09-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | PCR method |
CA2488823A1 (en) * | 2002-06-25 | 2003-12-31 | Index Pharmaceuticals Ab | Method and kit for the diagnosis of ulcerative colitis |
AU2003264512A1 (en) * | 2003-03-19 | 2004-10-11 | Hamamatsu Foundation For Science And Technology Promotion | Method of detecting colon cancer marker |
JP3805330B2 (ja) | 2003-08-20 | 2006-08-02 | 独立行政法人科学技術振興機構 | 大腸癌及び大腸腺腫の検査方法 |
DE10345021A1 (de) * | 2003-09-23 | 2005-05-04 | Univ Potsdam | Verfahren zur nichtinvasiven Früherkennung von Dickdarmkrebs und/oder Darmkrebsvorläuferzellen |
US20090148840A1 (en) | 2005-08-10 | 2009-06-11 | Hamamatsu Foundation For Science And Technology Promotion | Method for detecting colon cancer markers |
US7939255B2 (en) * | 2006-07-03 | 2011-05-10 | Catholic University Industry Academy Cooperation Foundation | Diagnostic methods for colorectal cancer |
-
2003
- 2003-09-19 AU AU2003264512A patent/AU2003264512A1/en not_active Abandoned
- 2003-09-19 US US10/549,389 patent/US7816077B2/en not_active Expired - Lifetime
- 2003-09-19 ES ES03816367T patent/ES2335344T3/es not_active Expired - Lifetime
- 2003-09-19 CN CN03826172.3A patent/CN100567985C/zh not_active Expired - Lifetime
- 2003-09-19 CA CA2518933A patent/CA2518933C/en not_active Expired - Fee Related
- 2003-09-19 JP JP2004569601A patent/JP4134047B2/ja not_active Expired - Lifetime
- 2003-09-19 WO PCT/JP2003/011972 patent/WO2004083856A1/ja active Application Filing
- 2003-09-19 AT AT03816367T patent/ATE451617T1/de not_active IP Right Cessation
- 2003-09-19 DE DE60330505T patent/DE60330505D1/de not_active Expired - Lifetime
- 2003-09-19 EP EP03816367A patent/EP1605261B1/en not_active Expired - Lifetime
-
2008
- 2008-04-21 JP JP2008109891A patent/JP4206425B2/ja not_active Expired - Lifetime
-
2009
- 2009-07-14 US US12/460,143 patent/US8080378B2/en not_active Expired - Lifetime
-
2010
- 2010-09-03 US US12/875,207 patent/US8445202B2/en not_active Expired - Fee Related
Non-Patent Citations (6)
Title |
---|
ALEXANDER R.J. ET AL, DIGESTIVE DISEASE AND SCIENCE, vol. 43, no. 12, 1998, pages 2652 - 2658, XP002904406 * |
DAVIDSON A.L. ET AL, CARCINOGENESIS, vol. 19, no. 2, 1998, pages 253 - 257, XP002075092 * |
JAPANESE JOURNAL OF GASTROENTEROLLOGY, vol. 99, 20 September 2002 (2002-09-20), pages A634 - P-379, XP002904408 * |
NAKAGAWA HIROKI: "Bio jikken illustrated 2 idenshi kaiseki no kiso", SHUJUNSHA CO. LTD., 25 September 1995 (1995-09-25), pages 153 - 166, XP002904403 * |
SANO H. ET AL, CANCER RESEARCH, vol. 55, no. 17, 1995, pages 3785 - 3789, XP002904407 * |
YAMAO T. ET AL, GASTROENTEROLOGY, vol. 114, no. 6, 1998, pages 1196 - 1205, XP002904405 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007018257A1 (ja) | 2005-08-10 | 2007-02-15 | Hamamatsu Foundation For Science And Technology Promotion | 大腸癌マーカー検出方法 |
EP1914318A4 (en) * | 2005-08-10 | 2008-11-26 | Hamamatsu Found Sci & Tech Pro | METHOD FOR DETECTING THICK-ARMED CANCER MARKERS |
JP4798514B2 (ja) * | 2005-08-10 | 2011-10-19 | 国立大学法人浜松医科大学 | 大腸癌マーカー検出方法 |
WO2008093530A1 (ja) * | 2007-01-30 | 2008-08-07 | National University Corporation, Hamamatsu University School Of Medicine | 大腸癌病期検出方法 |
JPWO2008093530A1 (ja) * | 2007-01-30 | 2010-05-20 | 国立大学法人浜松医科大学 | 大腸癌病期検出方法 |
JP2009065900A (ja) * | 2007-09-13 | 2009-04-02 | Olympus Corp | 標的rnaの解析方法及び保存方法 |
WO2009139317A1 (ja) * | 2008-05-12 | 2009-11-19 | オリンパス株式会社 | 糞便処理方法及び糞便処理容器 |
CN102027132A (zh) * | 2008-05-12 | 2011-04-20 | 奥林巴斯株式会社 | 粪便处理方法及粪便处理容器 |
US8597954B2 (en) | 2008-05-12 | 2013-12-03 | Olympus Corporation | Stool sample processing method and stool sample processing container |
JP2010161984A (ja) * | 2009-01-16 | 2010-07-29 | Chie Miyamoto | 癌関連遺伝子マーカーの検出方法 |
JP4538525B2 (ja) * | 2009-01-16 | 2010-09-08 | 千絵 宮本 | 癌関連遺伝子マーカーの検出方法 |
WO2012014694A1 (ja) * | 2010-07-26 | 2012-02-02 | オリンパス株式会社 | 糞便由来核酸の合成方法 |
Also Published As
Publication number | Publication date |
---|---|
US7816077B2 (en) | 2010-10-19 |
ATE451617T1 (de) | 2009-12-15 |
JP4134047B2 (ja) | 2008-08-13 |
ES2335344T3 (es) | 2010-03-25 |
US20060216714A1 (en) | 2006-09-28 |
CN100567985C (zh) | 2009-12-09 |
US20100323367A1 (en) | 2010-12-23 |
CA2518933A1 (en) | 2004-09-30 |
US8080378B2 (en) | 2011-12-20 |
CA2518933C (en) | 2012-04-03 |
JP2008271969A (ja) | 2008-11-13 |
EP1605261A1 (en) | 2005-12-14 |
US8445202B2 (en) | 2013-05-21 |
EP1605261A4 (en) | 2007-08-29 |
JPWO2004083856A1 (ja) | 2006-06-22 |
AU2003264512A1 (en) | 2004-10-11 |
DE60330505D1 (de) | 2010-01-21 |
JP4206425B2 (ja) | 2009-01-14 |
CN1759317A (zh) | 2006-04-12 |
EP1605261B1 (en) | 2009-12-09 |
US20090291447A1 (en) | 2009-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4206425B2 (ja) | 大腸癌マーカー検出方法 | |
EP3800273A1 (en) | Use of detection reagent for detecting methylation of genes associated with colorectal cancer, and kit | |
HUE019019T5 (en) | Methods for Using miRNA for In vivo Cell Death Detection | |
JP5851400B2 (ja) | 大腸腫瘍の検出方法 | |
JP4798514B2 (ja) | 大腸癌マーカー検出方法 | |
JP2008502330A (ja) | 乳癌の診断または経過の予測 | |
Kumar et al. | Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas | |
US7217515B2 (en) | HURP gene as a molecular marker for bladder cancer | |
US20140378334A1 (en) | Method for quantifying renal markers by assaying urine | |
JP5379350B2 (ja) | 胃がんのリンパ節転移の判定を補助する方法。 | |
JP2019531738A (ja) | 前立腺癌の診断と予後のためのインドールアミン−2,3−ジオキシゲナーゼ アッセイ | |
CN111733242A (zh) | lncRNA AK024561作为卵巢癌诊断标志物的应用 | |
JPWO2008093530A1 (ja) | 大腸癌病期検出方法 | |
JP4207187B2 (ja) | 膀胱癌に対する分子マーカーとしてのhurp遺伝子 | |
US20070259360A1 (en) | Marker for judging lymph node metastasis of breast cancer, a primer, and a method for judging lymph node metastasis of breast cancer using the marker | |
CN108384848B (zh) | 血清中circ_0021132作为深静脉血栓形成诊断标志物的应用 | |
JP2012080847A (ja) | 子宮頸癌のリンパ節転移の判定方法およびその判定装置 | |
Engel et al. | Detection of Tumor‐Specific mRNA in Cell‐Free Bronchial Lavage Supernatant in Patients with Lung Cancer | |
CN114592057A (zh) | 一种用于检测食管癌及其癌前病变的miRNA标志物试剂盒及应用 | |
JPWO2021125105A1 (ja) | 分析方法及びキット | |
JPWO2007132864A1 (ja) | プライマー、腫瘍マーカー、および癌の検出方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 4096/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2518933 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006216714 Country of ref document: US Ref document number: 10549389 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004569601 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038261723 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003816367 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003816367 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10549389 Country of ref document: US |